Your browser is no longer supported. Please, upgrade your browser.
Allena Pharmaceuticals, Inc.
Index- P/E- EPS (ttm)-1.03 Insider Own0.80% Shs Outstand57.28M Perf Week-6.09%
Market Cap59.72M Forward P/E- EPS next Y-1.11 Insider Trans-30.80% Shs Float43.97M Perf Month-13.60%
Income-32.80M PEG- EPS next Q-0.23 Inst Own36.90% Short Float3.28% Perf Quarter-47.32%
Sales- P/S- EPS this Y52.70% Inst Trans10.76% Short Ratio1.58 Perf Half Y-20.00%
Book/sh0.54 P/B2.00 EPS next Y-19.40% ROA-106.20% Target Price- Perf Year-42.55%
Cash/sh0.63 P/C1.71 EPS next 5Y- ROE-188.30% 52W Range1.02 - 3.39 Perf YTD-15.62%
Dividend- P/FCF- EPS past 5Y-7.80% ROI- 52W High-67.26% Beta2.17
Dividend %- Quick Ratio6.10 Sales past 5Y- Gross Margin- 52W Low8.82% ATR0.10
Employees41 Current Ratio6.10 Sales Q/Q- Oper. Margin- RSI (14)41.97 Volatility7.06% 9.03%
OptionableNo Debt/Eq0.00 EPS Q/Q49.50% Profit Margin- Rel Volume0.97 Prev Close1.08
ShortableYes LT Debt/Eq0.44 Earnings- Payout- Avg Volume913.27K Price1.11
Recom1.50 SMA20-4.56% SMA50-17.46% SMA200-22.67% Volume192,978 Change2.78%
Jun-01-20Initiated H.C. Wainwright Buy $10
Jul-10-19Resumed Credit Suisse Outperform
Jan-18-19Initiated Robert W. Baird Outperform $20
Dec-21-18Resumed B. Riley FBR Buy
Nov-08-18Resumed Jefferies Buy
Apr-25-18Initiated B. Riley FBR, Inc. Buy $23.50
Apr-02-18Initiated ROTH Capital Buy $61
May-12-21 06:09AM  
May-11-21 08:00AM  
May-04-21 04:01PM  
Apr-08-21 08:00AM  
Apr-07-21 08:00AM  
Mar-09-21 07:00AM  
Feb-24-21 08:00AM  
Feb-05-21 12:12AM  
Feb-02-21 08:00AM  
Jan-12-21 12:00PM  
Jan-04-21 08:00AM  
Dec-01-20 09:47PM  
Nov-30-20 08:00AM  
Nov-24-20 08:00AM  
Nov-09-20 08:00AM  
Nov-03-20 08:01AM  
Oct-21-20 11:58AM  
Oct-14-20 11:32AM  
Oct-06-20 12:00PM  
Oct-05-20 08:00AM  
Sep-30-20 08:00AM  
Sep-08-20 08:00AM  
Sep-03-20 08:00AM  
Aug-05-20 08:00AM  
Aug-04-20 08:00AM  
Jul-27-20 08:48PM  
Jul-16-20 03:27PM  
Jun-15-20 07:12PM  
Jun-03-20 01:15PM  
Jun-02-20 07:45AM  
May-26-20 08:00AM  
May-13-20 08:00AM  
Apr-22-20 12:00PM  
Mar-18-20 12:00PM  
Mar-16-20 08:00AM  
Feb-24-20 08:00AM  
Feb-13-20 08:05AM  
Feb-12-20 07:00AM  
Jan-28-20 01:48PM  
Jan-14-20 12:00PM  
Dec-16-19 01:45PM  
Dec-05-19 07:14AM  
Dec-04-19 05:00PM  
Nov-25-19 08:00AM  
Nov-18-19 06:19AM  
Nov-13-19 08:01AM  
Nov-08-19 08:14AM  
Nov-07-19 06:55AM  
Oct-17-19 08:00AM  
Oct-08-19 09:00AM  
Sep-16-19 08:00AM  
Sep-11-19 08:00AM  
Aug-29-19 08:00AM  
Aug-07-19 08:00AM  
Aug-06-19 08:00AM  
Aug-02-19 11:46AM  
Aug-01-19 11:55AM  
Jul-31-19 09:05AM  
Jul-29-19 10:04AM  
Jul-26-19 10:53AM  
Jul-25-19 07:37AM  
Jun-27-19 08:45PM  
Jun-21-19 08:00AM  
Jun-15-19 12:38PM  
Jun-04-19 08:00AM  
May-30-19 08:00AM  
May-08-19 09:00AM  
Apr-17-19 09:02AM  
Mar-27-19 08:00AM  
Mar-07-19 08:01AM  
Mar-05-19 08:00AM  
Jan-04-19 08:00AM  
Jan-02-19 08:00AM  
Dec-23-18 09:21PM  
Nov-19-18 08:25AM  
Nov-07-18 08:00AM  
Nov-06-18 04:01PM  
Oct-25-18 08:00AM  
Oct-22-18 08:00AM  
Oct-18-18 08:00AM  
Sep-25-18 08:00AM  
Aug-07-18 04:01PM  
Jul-27-18 07:36AM  
Jul-12-18 07:48AM  
Jun-19-18 08:00AM  
Jun-11-18 08:00AM  
May-30-18 08:00AM  
May-08-18 08:00AM  
Apr-20-18 05:54PM  
Apr-04-18 11:21AM  
Allena Pharmaceuticals, Inc., a late-stage clinical biopharmaceutical company, engages in the development and commercialization of oral enzyme therapeutics to treat patients with rare and severe metabolic, and kidney disorders in the United States. The company's lead product candidate is reloxaliase, an oral enzyme therapeutic that is in phase 3 clinical program for the treatment of hyperoxaluria, a metabolic disorder commonly associated with kidney stones in adults. It also develops ALLN-346, a novel and urate degrading enzyme for patients with hyperuricemia and moderate to severe chronic kidney diseases. Allena Pharmaceuticals, Inc. was incorporated in 2011 and is headquartered in Newton, Massachusetts.
Insider Trading Relationship Date Transaction Cost #Shares Value ($) #Shares Total SEC Form 4
BRENNER LOUIS MDPresident and COOMay 10Sale1.1125,21527,989203,322May 12 04:45 PM
BRENNER LOUIS MDPresident and CEODec 17Sale1.36103,116140,238144,816Dec 18 04:15 PM
WHOLIHAN EDWARDChief Financial OfficerDec 17Sale1.3668,55093,228121,272Dec 18 04:15 PM